|By Marketwired .||
|June 25, 2014 08:16 AM EDT||
LOS ANGELES, CA and HOUSTON, TX -- (Marketwired) -- 06/25/14 -- MMRGlobal, Inc. (OTCQB: MMRF), through its wholly owned subsidiary, MyMedicalRecords, Inc. (collectively, "MMR"), and Salutopia, Inc. jointly announced the signing of a patent license agreement. The agreement calls for MMR to receive license fees based on a percentage of the gross sales of Salutopia products and services currently projected at more than $50,000,000 based on Salutopia's sales pipeline. In exchange, Salutopia benefits from rights to MMR's growing portfolio of U.S. health information technology patents and all additional applications that are pending in the United States. Salutopia is a leading Texas-based clinical data aggregator and provider of content connecting disparate Electronic Medical Record systems, practice management systems and patient portals. The agreement gives Salutopia the ability to deliver its products and services with MMR's licensed intellectual property inside, while also allowing Salutopia to offer selected MMR proprietary features and benefits from the MyMedicalRecords Personal Health Record (PHR). The agreement also allows MMR to offer selected proprietary products and services from Salutopia.
The relationship gives MMR and its patented intellectual property greater exposure to the healthcare IT vertical. As a market leader of integrated clinical data aggregation, Salutopia provides patients, providers and payers, including insurance companies, hospital networks, MCOs, Home Health Care organizations, ACOs (Accountable Care Organizations), IPAs (Independent Physicians Associations), Health Information Exchanges, and others, seamless interoperability of patient data across all Electronic Health Record technology systems, simplifying interconnectivity between diverse systems.
According to Fred Zolla, Chairman and Chief Strategy Officer for Salutopia, "Incorporating MMR's licensed products in our current service offerings ensures our clients a higher level of protection and gives us an advantage over our competitors."
MMR's global health information technology patent portfolio includes 12 issued U.S. patents: U.S. Patent Nos. 8,768,725, 8,121,855; 8,117,045; 8,117,646; 8,301,466; 8,321,240; 8,352,287; 8,352,288; 8,498,883; 8,626,532; 8,645,161, and 8,725,537, in addition to a recently issued Notice of Allowance from the United States Patent and Trademark Office for U.S. Application Serial No. 13/082,896, which collectively include over 290 issued claims, along with additional applications and continuation applications pending. MMR also has received issued patents and has pending applications in 11 other countries or regional authorities of commercial interest including Australia, Canada, Singapore, New Zealand, Mexico, Hong Kong, China, Japan, South Korea, Israel, and Europe.
Using MMR's patented IP, Salutopia is planning on expanding their patient portals to make it possible for patients to access, collect and manage all their medical records, including prescriptions, online in a secure and private manner. The service will also achieve, individually and collectively, seamless interoperability with one historic consolidated medical record for patients and all their family members regardless of the number of physicians and the technology on the other end of the PHR. Using MMR's patented IP, Salutopia also provides patients, any number of treating doctors, and other healthcare professionals (including emergency room physicians and staff) access to complete, secure and private medical information whenever and wherever it's needed from anywhere in the world. The Salutopia patient portal can reduce healthcare costs, eliminate unnecessary duplicate testing and delays in obtaining treatment, as well as other wasteful and potentially dangerous practices facing patients. Together, both companies enable patients to be involved in their own healthcare through modern communication and direct access to their complete medical history.
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. MMR's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, MMR acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId/Specifid vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of MMR's products and services at www.mmrtheater.com. Follow us at Facebook.com/MMRGlobal and Twitter.com/mmrglobal.
Salutopia, founded in 1995 and headquartered in Houston, TX, is an industry leader in providers, patients and insurance companies a reality. Salutopia leverages its rich healthcare information technology experience to bring proprietary solutions that redefine on-demand availability. To learn more about Salutopia, visit www.salutopia.com.
All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property licenses, intellectual property enforcement actions, infringement claims or litigation, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MMR's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, license, monetize and protect our patent portfolio for both MMR's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk MMR's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in MMR's filings with the Securities and Exchange Commission. MMR is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smart...
Dec. 11, 2016 03:30 AM EST Reads: 1,114
Dec. 11, 2016 03:00 AM EST Reads: 787
Dec. 11, 2016 02:45 AM EST Reads: 902
Dec. 11, 2016 02:45 AM EST Reads: 1,801
Dec. 11, 2016 02:30 AM EST Reads: 1,051
Dec. 11, 2016 02:30 AM EST Reads: 1,295
Dec. 11, 2016 01:45 AM EST Reads: 745
Dec. 11, 2016 01:45 AM EST Reads: 4,051
Dec. 11, 2016 01:30 AM EST Reads: 1,751
Dec. 11, 2016 01:15 AM EST Reads: 1,335
Dec. 11, 2016 12:00 AM EST Reads: 2,400
Dec. 11, 2016 12:00 AM EST Reads: 941
Dec. 11, 2016 12:00 AM EST Reads: 1,131
Dec. 10, 2016 11:15 PM EST Reads: 1,223
Dec. 10, 2016 10:15 PM EST Reads: 2,076